Results 51 to 60 of about 244,949 (162)

Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer

İstanbul Medical Journal
Introduction: Adding targeted agents to chemotherapy for metastatic colorectal cancer increases survival. There have been no clinical trials in older populations comparing the efficacy of the targeted agents.
Ender Doğan, Sedat Tarık Fırat, Murat Eser, Oktay Bozkurt, Mevlüde İnanç, Metin Özkan   +5 more
doaj   +1 more source

Clinical preferences and trends of anti‐vascular endothelial growth factor treatments for diabetic macular edema in Japan

Journal of Diabetes Investigation, 2019
Aims/Introduction To determine the current clinical preferences of anti‐vascular endothelial growth factor (VEGF) treatment protocols for diabetic macular edema (DME) in Japan. Materials and Methods This was a descriptive cross‐sectional study.
Masahiko Sugimoto, Hideyuki Tsukitome, Fumiki Okamoto, Tetsuro Oshika, Tetsuo Ueda, Masanori Niki, Yoshinori Mitamura, Hiroto Ishikawa, Fumi Gomi, Shigehiko Kitano, Hidetaka Noma, Masahiko Shimura, Shozo Sonoda, Osamu Sawada, Masahito Ohji, Kozo Harimoto, Masaru Takeuchi, Yoshihiro Takamura, Mineo Kondo, Taiji Sakamoto   +19 more
doaj   +1 more source

Is There a Relationship Between Use of Anti-Vascular Endothelial Growth Factor Agents and Atrophic Changes in Age-Related Macular Degeneration Patients?

Türk Oftalmoloji Dergisi, 2018
Choroidal neovascularization due to age-related macular degeneration (AMD) is currently treated successfully with anti-vascular endothelial growth factor (VEGF) intravitreal agents.
Süleyman Kaynak, Mahmut Kaya, Derya Kaya   +2 more
doaj   +1 more source

A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.

PLoS Medicine, 2008
BackgroundVascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy
Kiyoshi Masuda, Shigetada Teshima-Kondo, Mina Mukaijo, Naoko Yamagishi, Yoshiko Nishikawa, Kensei Nishida, Tomoko Kawai, Kazuhito Rokutan   +7 more
doaj   +1 more source

Anti-VEGF in a Marathon Runner’s Retinopathy Case

Case Reports in Ophthalmological Medicine, 2016
Central retinal vein occlusion (CRVO) is one of the most common retinal vascular disorders. Intense exercise associated CRVO have been described in otherwise healthy young patients. We describe a case of a young male ultramarathoner who presented with a CRVO, presumably associated with dehydration, making part of a marathon runner’s retinopathy ...
Alexander Kahjun Soon, Paulo Ricardo Chaves de Oliveira, David Robert Chow   +2 more
openaire   +4 more sources

Synergistic effects of traditional Chinese medicine and anti-VEGF therapy on diabetic retinopathy progression: Insights into pharmacological mechanisms and clinical outcomes

Pakistan Journal of Pharmaceutical Sciences
This study investigated the effects of combining traditional Chinese medicine (TCM) with anti-VEGF therapy in diabetic retinopathy (DR) and diabetic macular edema (DME). A total of 119 cases with DME were divided into the anti-VEGF treatment group (n=56)
Xianlin Zhou, Lin Kong, Qihong Wu
doaj   +1 more source

Tumor refractoriness to anti-VEGF therapy

Oncotarget, 2016
Vascular endothelial growth factor (VEGF) has been identified as the most potent cytokine involved in tumor angiogenesis and metastasis formation. Clinical results of anti-angiogenic therapies targeting VEGF and its receptors are very modest, resulting in a moderate improvement of overall survival.
openaire   +4 more sources

Evaluation of microaneurysms as predictors of therapeutic response to anti-VEGF therapy in patients with DME

PLoS ONE, 2022
Administration of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line therapy for diabetic macular oedema (DME). However, some patients show no or insufficient response to repeated anti-VEGF injections.
Makoto Hatano, Fumiaki Higashijima, Takuya Yoshimoto, Tadahiko Ogata, Manami Ohta, Yuka Kobayashi, Makiko Wakuta, Ryoji Yanai, Kazuhiro Kimura   +8 more
doaj  

Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice

Scientific Reports
Medication-related osteonecrosis of the jaw (MRONJ) is a detrimental side effect in patients undergoing treatment with antiresorptive agents. The anti-angiogenic agent, bevacizumab (anti-VEGF antibody (Ab)), has also been reported to be associated with ...
Eun-Bin Bae, Moon-Young Kim, Suk Ji, In-Woo Cho, Soo Yeon Kim, Maryam Esmaeili, Sherry S. Baik, Sol Kim, Sotirios Tetradis, No-Hee Park, Yousang Gwack, Reuben H. Kim   +11 more
doaj   +1 more source

Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead

Indian Journal of Ophthalmology
The emergence of anti-vascular endothelial growth factor (anti-VEGF) therapy has marked a paradigm shift in the treatment of retinal and choroidal vascular diseases.
Chitaranjan Mishra, Nabatika Mohanty, Somy Purohit, Udayasree Orugonda, Vaishnavi Patil   +4 more
doaj   +1 more source